Literature DB >> 7956266

Field trials of tuberculosis vaccines: how could we have done them better?

G W Comstock1.   

Abstract

Nineteen controlled trials of vaccination against tuberculosis are reviewed. Most involved very large numbers of participants and represented a wide variety of geographic and socioeconomic conditions. The trials were conducted under field conditions that sometimes verged on the primitive. Length of follow-up for tuberculosis ranged from 3 to 23 years, and up to 28 years for cancer. Under these circumstances, compromises and mistakes were made along with notable successes. With the current interest in the immunology of tuberculosis and other chronic infectious diseases giving rise to renewed hope for more efficacious vaccines, lessons from the past can be useful in planning the long-term evaluations that will be needed as these hoped-for vaccines become available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956266     DOI: 10.1016/0197-2456(94)90042-6

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  25 in total

1.  Mycobacterium tuberculosis-secreted protein antigens: immunogenicity in baboons.

Authors:  K Pehler; K M Brasky; T M Butler; R Attanasio
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 2.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Tuberculosis control: challenges of an ancient and ongoing epidemic.

Authors:  Kristin J Cummings
Journal:  Public Health Rep       Date:  2007 Sep-Oct       Impact factor: 2.792

4.  Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes.

Authors:  M Abolhassani; M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 5.  Genetic vaccination against tuberculosis.

Authors:  D B Lowrie; C L Silva; R E Tascon
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Tuberculosis knowledge, attitudes, and beliefs in foreign-born and US-born patients with latent tuberculosis infection.

Authors:  Paul W Colson; Julie Franks; Rita Sondengam; Yael Hirsch-Moverman; Wafaa El-Sadr
Journal:  J Immigr Minor Health       Date:  2010-12

7.  An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine-secreting BCG vaccines.

Authors:  L Slobbe; E Lockhart; M A O'Donnell; C MacKintosh; G De Lisle; G Buchan
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

8.  The tuberculosis epidemic. Scientific challenges and opportunities.

Authors:  A M Ginsberg
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

9.  Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines.

Authors:  Adam Belley; David Alexander; Tania Di Pietrantonio; Manon Girard; Joses Jones; Erwin Schurr; Jun Liu; David R Sherman; Marcel A Behr
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 10.  Do antenatal parasite infections devalue childhood vaccination?

Authors:  A Desiree Labeaud; Indu Malhotra; Maria J King; Christopher L King; Charles H King
Journal:  PLoS Negl Trop Dis       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.